Bone Mineral Density

Comparison Evaluating Bone Mineral Density Changes in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

The current standard hormone therapy (ADT) for men with advanced prostate cancer is a class of drugs called Luteinising hormone-releasing hormone agonists (LHRHa). These drugs reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss as a side effect of the ADT. Using transdermal (skin patches) oestradiol is a potential alternative to [...]

By |2016-04-05T12:04:43-04:00April 5th, 2016|Advanced Prostate Cancer, Bone Health, Bone Mineral Density, Bones and Prostate Cancer, Drugs & Treatments, estrogen patches, Hormone Therapy, Research, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments
Read More

Prevalence of Fractures Among Men with Stage IV Prostate Cancer

Many of us believe that the risk developing bone fractures is more common in men who have stage 4 prostate cancer that has developed distant metastasis than those men with stage 4 prostate cancer that do not have distant metastasis.  This increased risk, or actually the increase of fractures has significant clinical consequences, such as [...]